vildagliptin + placebo of vildagliptin
ApprovedCompleted 0 watching 0 views this weekπ₯ Hot
85
Development Stage
β
Pre-clinicalβ
Phase 1β
Phase 2β
Phase 35
ApprovedIndication / Disease
Congestive Heart Failure
Conditions
Congestive Heart Failure, Type II Diabetes Mellitus
Trial Timeline
May 1, 2009 β Aug 1, 2012
NCT ID
NCT00894868About vildagliptin + placebo of vildagliptin
vildagliptin + placebo of vildagliptin is a approved stage product being developed by Novartis for Congestive Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT00894868. Target conditions include Congestive Heart Failure, Type II Diabetes Mellitus.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00894868 | Approved | Completed |
Competing Products
20 competing products in Congestive Heart Failure
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IV diuretic | Nuwellis | Pre-clinical | 15 |
| Carperitide + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Seloken ZOK/Toprol-XL + Seloken ZOK/Toprol-XL + Placebo | AstraZeneca | Phase 3 | 77 |
| Candesartan + Placebo | AstraZeneca | Phase 3 | 77 |
| AC2592 + placebo | AstraZeneca | Phase 2 | 52 |
| Dapagliflozin + Placebo | AstraZeneca | Approved | 85 |
| Enoximone + Metoprolol succinate + Placebo to match enoximone + Placebo to match metoprolol succinate | AstraZeneca | Phase 3 | 77 |
| Candesartan + Placebo | AstraZeneca | Phase 3 | 77 |
| Candesartan + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| KW-3902IV | Merck | Phase 2 | 52 |
| rolofylline + Comparator: Placebo (unspecified) | Merck | Phase 3 | 77 |
| KW-3902IV | Merck | Phase 2 | 52 |
| Sitagliptin | Merck | Phase 1 | 33 |
| Low Dose Bisoprolol + High Dose Bisoprolol | Merck | Approved | 85 |
| rolofyline + Comparator Placebo (unspecified) | Merck | Phase 2 | 52 |
| rolofylline + Comparator: Placebo (unspecified) | Merck | Phase 3 | 77 |
| rolofylline + Comparator: Placebo (unspecified) | Merck | Phase 3 | 77 |
| Relaxin + Placebo | Novartis | Phase 2/3 | 65 |
| Relaxin | Novartis | Phase 2 | 52 |